# Biotech Daily Digest â€” 2025-11-20

**43 items from 5 sources**

## Summary by Source

- Endpoints News: 13 items
- Fierce Biotech: 5 items
- MHRA â€“ News: 2 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 22 items


## Endpoints News

- **[Flagship and portfolio companies do deals with GSK, Merck KGaA and Saudi Arabia](https://endpoints.news/flagship-and-portfolio-companies-do-deals-with-gsk-merck-kgaa-and-saudi-arabia/)**  
  _Thu, 20 Nov 2025 14:27:08 +0000_  
  Flagship Pioneering and its sprawling apparatus of biotech startups struck a series of deals this week with GSK, Merck KGaA and a large medical research institute in Saudi Arabia.



 The Boston-area investor and incubator, which ...

- **[FDA approves new indication and monthly dose of Regeneronâ€™s Eylea HD](https://endpoints.news/fda-approves-new-indication-and-monthly-dose-of-regenerons-eylea-hd/)**  
  _Thu, 20 Nov 2025 14:14:22 +0000_  
  The FDA has okayed Regeneron Pharmaceuticalsâ€™ Eylea HD injection for another indication and as a monthly dosing option, despite issues at its third-party manufacturing site run by Novo Nordisk.

 Regeneron secured approvals for Eylea HD ...

- **[Aspen gets $115M for Parkinson's cell therapy, potential IPO in sight next year](https://endpoints.news/aspen-gets-115m-for-parkinsons-cell-therapy-potential-ipo-in-sight-next-year/)**  
  _Thu, 20 Nov 2025 12:02:48 +0000_  
  Aspen Neuroscience will put itself to the test in 2026.

 The San Diego biotech aims to enter Phase 3 with its lead cell therapy for Parkinson's disease next year, CEO Damien McDevitt told Endpoints News ...

- **[Post-Hoc Live: The drug industryâ€™s Mr. Reality Check, Derek Lowe](https://endpoints.news/post-hoc-live-the-drug-industrys-mr-reality-check-derek-lowe/)**  
  _Thu, 20 Nov 2025 12:00:14 +0000_  
  For years, every time there was a controversial decision in biopharma, an interesting discovery in chemistry, or an oversupply of enthusiasm for an idea or technology, Derek Lowe often has had something to say.  ...

- **[Novartis raises the sales bar for key cancer drugs, tweaks yearly growth guidance](https://endpoints.news/novartis-raises-the-sales-bar-for-key-cancer-drugs-tweaks-yearly-growth-guidance/)**  
  _Thu, 20 Nov 2025 11:43:02 +0000_  
  Novartis said it has shifted the range of its mid-term growth target due to higher peak sales projections for some of its key medicines, as well as other growth drivers in its pipeline.

 The Swiss ...

- **[Innovent to seek China approval of high-dose obesity shot after Phase 3 hit](https://endpoints.news/innovent-to-seek-china-approval-of-high-dose-obesity-shot-after-phase-3-hit/)**  
  _Thu, 20 Nov 2025 11:30:31 +0000_  
  A high-dose version of Innovent Biologicsâ€™ obesity drug led to patients with moderate-to-severe disease losing 18.6% of their body weight in about a year and two months, according to data from a late-stage China-based trial ...

- **[Pfizer CFO says drugmaker will 'supplement' Metsera deal as part of broader obesity ambitions](https://endpoints.news/pfizer-cfo-says-drugmaker-will-supplement-metsera-deal-as-part-of-broader-obesity-ambitions/)**  
  _Wed, 19 Nov 2025 19:27:38 +0000_  
  Now that Pfizer has acquired Metsera, the New York drug giant is likely to be peppered with questions about its obesity R&D strategy going forward.

 That was evident during Pfizer CFO Dave ...

- **[New tuberculosis treatment shows potential in a Phase 2 study](https://endpoints.news/new-tuberculosis-treatment-shows-potential-in-a-phase-2-study/)**  
  _Wed, 19 Nov 2025 19:05:40 +0000_  
  A new antibiotic for tuberculosis outperformed other treatment options without compromising safety in drug-sensitive patients, according to trial results released Wednesday.

 TB Alliance reported that the experimental drug sorfequiline, when combined ...

- **[Agios' sickle cell trial falls short as drug doesn't appear to help patient pain crises](https://endpoints.news/agios-sickle-cell-trial-falls-short-as-drug-doesnt-appear-to-help-patient-pain-crises/)**  
  _Wed, 19 Nov 2025 16:28:26 +0000_  
  Agios Pharmaceuticalsâ€™ drug Pyrukynd hit only one of the two primary endpoints in its pivotal trial in sickle cell disease, the company said Wednesday, a significant setback for the company's plans ...

- **[New prime editing approach could create one-size-fits-many therapies](https://endpoints.news/new-prime-editing-approach-could-create-one-size-fits-many-therapies/)**  
  _Wed, 19 Nov 2025 16:17:20 +0000_  
  Researchers led by Broad Institute gene editing star David Liu have come up with a new use for prime editing that can tackle a bucket of diseases with the same root cause, which they say ...

- **[Protara trumpets small rare disease dataset in children for cell therapy](https://endpoints.news/protara-trumpets-small-rare-disease-dataset-in-children-for-cell-therapy/)**  
  _Wed, 19 Nov 2025 15:57:02 +0000_  
  Protara Therapeutics on Wednesday revealed new data showing its experimental bladder cancer cell therapy could also have potential in a rare pediatric disease.

 In a small, open-label Phase 2 dataset, Protaraâ€™s TARA-002

- **[Merck says once-daily HIV drug combo succeeds in another Phase 3](https://endpoints.news/merck-says-once-daily-hiv-drug-combo-succeeds-in-another-phase-3/)**  
  _Wed, 19 Nov 2025 14:51:35 +0000_  
  Merck secured another win on Wednesday in its plan to bolster its HIV portfolio.

 The pharma giant said its two-drug combination was non-inferior to a three-drug package in a Phase 3 ...

- **[Pfizer's antibody pact with Nona Biosciences; Epkinly's label expansion](https://endpoints.news/pfizers-antibody-pact-with-nona-biosciences-epkinlys-label-expansion/)**  
  _Wed, 19 Nov 2025 14:45:01 +0000_  
  Plus, news about GSK, Eledon, Hanmi Pharmaceutical, Aptose Biosciences, Rafa Laboratories and Eli Lilly:

 ðŸ”¬ Pfizerâ€™s preclinical antibody discovery deal with Nona Biosciences: In a non-exclusive licensing partnership, Pfizer will ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/aspen-enriches-parkinsons-cell-therapy-trial-kite-backed-115m-series-c" hreflang="en">Aspen enriches Parkinson's cell therapy trial with Kite-backed $115M series C</a>](https://www.fiercebiotech.com/biotech/aspen-enriches-parkinsons-cell-therapy-trial-kite-backed-115m-series-c)**  
  _Nov 19, 2025 5:04pm_  
  Aspen Neuroscienceâ€™s cash reserves have been fertilized with a $115 million series C fundraising that will enrich the biotechâ€™s ongoing trial of a regenerative cell therapy for Parkinsonâ€™s disease.

- **[<a href="https://www.fiercebiotech.com/biotech/3b-deal-merck-kgaa-becomes-latest-big-pharma-partner-drug-discoverer-valo-health" hreflang="en">Merck KGaA links up with Flagship's Valo Health in search for Parkinson's targets, offers $3B in biobucks</a>](https://www.fiercebiotech.com/biotech/3b-deal-merck-kgaa-becomes-latest-big-pharma-partner-drug-discoverer-valo-health)**  
  _Nov 19, 2025 2:19pm_  
  Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneeringâ€™s Valo Health. The German drugmaker has inked a deal to harness Valoâ€™s reams of human biology data to find new therapeutic targets for Parkinsonâ€™s disease, offering a potential payout eclipsing $3 billion in return.

- **[<a href="https://www.fiercebiotech.com/biotech/novartis-ceo-paid-top-dollar-avidity-become-leader-neuromuscular-diseases" hreflang="en">Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases'</a>](https://www.fiercebiotech.com/biotech/novartis-ceo-paid-top-dollar-avidity-become-leader-neuromuscular-diseases)**  
  _Nov 20, 2025 4:38am_  
  Novartis may have signed off on the second-largest pharma acquisition of 2025 so far, but, as the companyâ€™s CEO sees itâ€”itâ€™s never about the price tag.

- **[<a href="https://www.fiercebiotech.com/medtech/lumexa-imaging-eyes-public-offering-expected-raise-200m" hreflang="en">Radiology provider Lumexa Imaging eyes IPO expected to raise $200M</a>](https://www.fiercebiotech.com/medtech/lumexa-imaging-eyes-public-offering-expected-raise-200m)**  
  _Nov 19, 2025 8:55am_  
  Lumexa Imaging, known as US Radiology Specialists until this year, has filed with the SEC to go public and is set to raise as much as $200 million.

- **[<a href="https://www.fiercebiotech.com/biotech/tempest-turns-factor-lifeline-trading-majority-stake-car-ts-and-ceo" hreflang="en">Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO</a>](https://www.fiercebiotech.com/biotech/tempest-turns-factor-lifeline-trading-majority-stake-car-ts-and-ceo)**  
  _Nov 19, 2025 11:43am_  
  After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing the latterâ€™s CEO on board to helm the company.


## MHRA â€“ News

- **[Transparency data: MHRA Performance Data](https://www.gov.uk/government/publications/mhra-performance-data)**  
  _2025-11-20T12:30:36Z_  
  Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.

- **[Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Fingolimod SUN 0.5mg hard capsules, EL(25)A/49](https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-sun-pharmaceutical-industries-limited-fingolimod-sun-0-dot-5mg-hard-capsules-el-25-a-slash-49)**  
  _2025-11-20T11:05:55Z_  
  Sun Pharma UK Limited is conducting a precautionary recall of a single batch of Fingolimod SUN 0.5 mg hard capsules due to reports of capsule breakage on removing from the blister. No other batches of Fingolimod SUN 0.5mg hard capsules are impacted.


## Regeneron Press Releases

- **[EYLEA HDÂ® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications](https://investor.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-approved-fda-treatment)**  
  _Wed, 19 Nov 2025 16:10:00 -0500_  
  First and only FDA-approved treatmentÂ  for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y. , Nov.


## arXiv q-bio

- **[Quantifying the Role of OpenFold Components in Protein Structure Prediction](https://arxiv.org/abs/2511.14781)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.14781v1 Announce Type: new 
Abstract: Models such as AlphaFold2 and OpenFold have transformed protein structure prediction, yet their inner workings remain poorly understood. We present a methodology to systematically evaluate the contribution of individual OpenFold components to structure prediction accuraâ€¦

- **[MergeDNA: Context-aware Genome Modeling with Dynamic Tokenization through Token Merging](https://arxiv.org/abs/2511.14806)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.14806v1 Announce Type: new 
Abstract: Modeling genomic sequences faces two unsolved challenges: the information density varies widely across different regions, while there is no clearly defined minimum vocabulary unit. Relying on either four primitive bases or independently designed DNA tokenizers, existingâ€¦

- **[XGBoost-Powered Digital Twins Leverage Routine Blood Tests for Early Detection of Cancer and Cardiovascular Disease](https://arxiv.org/abs/2511.14816)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.14816v1 Announce Type: new 
Abstract: Early detection of cancer and cardiovascular diseases is fundamental to improving patient outcomes and reducing healthcare expenditure. Current cancer screening programs are targeted towards specific cancers and are often inaccessible to large parts of the population, pâ€¦

- **[Leveraging NCBI Genomic Metadata for Epidemiological Insights: Example of Enterobacterales](https://arxiv.org/abs/2511.14826)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.14826v1 Announce Type: new 
Abstract: Numerous studies have utilized NCBI data for genomic analysis, gene annotation, and identifying disease-associated variants, yet NCBI's epidemiological potential remains underexplored. This study demonstrates how NCBI datasets can be systematically leveraged to extractâ€¦

- **[Maximum entropy models of neuronal populations at and off criticality](https://arxiv.org/abs/2511.14872)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.14872v1 Announce Type: new 
Abstract: Empirical evidence of scaling behaviors in neuronal avalanches suggests that neuronal populations in the brain operate near criticality. Departure from scaling in neuronal avalanches has been used as a measure of distance to criticality and linked to brain disorders. Aâ€¦

- **[Izzy: a high-throughput metagenomic read simulator](https://arxiv.org/abs/2511.14909)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.14909v1 Announce Type: new 
Abstract: Simulated microbial communities are used in benchmarking microbial abundance estimators and other bioinformatic utilities. To match current data scales, large simulated samples are needed, and many. The speed of current implementations might create bottlenecks for scienâ€¦

- **[Teaching signal synchronization in deep neural networks with prospective neurons](https://arxiv.org/abs/2511.14917)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.14917v1 Announce Type: new 
Abstract: Working memory requires the brain to maintain information from the recent past to guide ongoing behavior. Neurons can contribute to this capacity by slowly integrating their inputs over time, creating persistent activity that outlasts the original stimulus. However, wheâ€¦

- **[The role of antibody-mediated immunity in shaping the seasonality of respiratory viruses](https://arxiv.org/abs/2511.15070)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15070v1 Announce Type: new 
Abstract: In temperate regions, respiratory virus epidemics recur on a yearly basis, primarily during the winter season. This is believed to be induced by seasonal forcing, where the rate at which the virus can be transmitted varies cyclically across the course of each year. Seasâ€¦

- **[CASPER: Cross-modal Alignment of Spatial and single-cell Profiles for Expression Recovery](https://arxiv.org/abs/2511.15139)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15139v1 Announce Type: new 
Abstract: Spatial Transcriptomics enables mapping of gene expression within its native tissue context, but current platforms measure only a limited set of genes due to experimental constraints and excessive costs. To overcome this, computational models integrate Single-Cell RNA Sâ€¦

- **[Detection of spiking motifs of arbitrary length in neural activity using bounded synaptic delays](https://arxiv.org/abs/2511.15296)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15296v1 Announce Type: new 
Abstract: In the context of spiking neural networks, temporal coding of signals is increasingly preferred over the rate coding hypothesis due to its advantages in processing speed and energy efficiency. In temporal coding, synaptic delays are crucial for processing signals with pâ€¦

- **[Modulating the tennis racket grip during motor imagery influences serve accuracy and performance: A pilot study](https://arxiv.org/abs/2511.15298)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15298v1 Announce Type: new 
Abstract: There is now ample evidence that Motor Imagery (MI) contributes to improve motor performance. Previous studies provided evidence that its effectiveness remains dependent upon specific guidelines and recommendations. The body posture, as well as the context in which MI iâ€¦

- **[Does the Muller-Lyer illusion induced by a goalkeeper configuration influence soccer penalty kicks?](https://arxiv.org/abs/2511.15338)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15338v1 Announce Type: new 
Abstract: In soccer penalty kicks, goalkeepers that orient their arms upward compared to downward can be misperceived as being taller - effectively recreating the Muller-Lyer illusion. The present study elaborates on previous research surrounding a potential illusion-induced biasâ€¦

- **[Methods for Secondary and Tertiary Structure Prediction of Microproteins](https://arxiv.org/abs/2511.15628)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15628v1 Announce Type: new 
Abstract: Microproteins are a newly recognized and rapidly growing class of small proteins, typically encoded by fewer than 100 to 150 codons and translated from small open reading frames (smORFs). Although research has shown that smORFs and their corresponding microproteins consâ€¦

- **[Deep Pathomic Learning Defines Prognostic Subtypes and Molecular Drivers in Colorectal Cancer](https://arxiv.org/abs/2511.15067)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15067v1 Announce Type: cross 
Abstract: Precise prognostic stratification of colorectal cancer (CRC) remains a major clinical challenge due to its high heterogeneity. The conventional TNM staging system is inadequate for personalized medicine. We aimed to develop and validate a novel multiple instance learnâ€¦

- **[BaGGLS: A Bayesian Shrinkage Framework for Interpretable Modeling of Interactions in High-Dimensional Biological Data](https://arxiv.org/abs/2511.15330)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15330v1 Announce Type: cross 
Abstract: Biological data sets are often high-dimensional, noisy, and governed by complex interactions among sparse signals. This poses major challenges for interpretability and reliable feature selection. Tasks such as identifying motif interactions in genomics exemplify theseâ€¦

- **[Chemical systems with chaos](https://arxiv.org/abs/2511.15554)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15554v1 Announce Type: cross 
Abstract: Three-dimensional polynomial dynamical systems (DSs) can display chaos with various properties already in the quadratic case with only one or two quadratic monomials. In particular, one-wing chaos is reported in quadratic DSs with only one quadratic monomial, while twâ€¦

- **[Kinetic and mean-field modeling of muscular dystrophies](https://arxiv.org/abs/2511.15599)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2511.15599v1 Announce Type: cross 
Abstract: We present a new class of models for assessing the cell dynamics characterising muscular dystrophies. The proposed approach comprises a system of integro-differential equations for the statistical distributions, over a large patient cohort, of the densities of muscleâ€¦

- **[Eco-evolutionary constraints for the endemicity of rapidly evolving viruses](https://arxiv.org/abs/2411.02097)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2411.02097v2 Announce Type: replace 
Abstract: Antigenic escape constitutes the main mechanism allowing rapidly evolving viruses to achieve endemicity. Beyond granting immune escape, empirical evidence also suggests that mutations of viruses might increase their inter-host infectiousness. While both mechanisms aâ€¦

- **[Explicit modeling of density dependence in spatial capture-recapture models](https://arxiv.org/abs/2412.09431)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2412.09431v2 Announce Type: replace 
Abstract: Density dependence occurs at the individual level and thus is greatly influenced by spatial local heterogeneity in habitat conditions. However, density dependence is often evaluated at the population level, leading to difficulties or even controversies in detectingâ€¦

- **[A meaningful prediction of functional decline in amyotrophic lateral sclerosis based on multi-event survival analysis](https://arxiv.org/abs/2506.02076)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2506.02076v2 Announce Type: replace 
Abstract: Amyotrophic lateral sclerosis (ALS) is a degenerative disorder of the motor neurons that causes progressive paralysis in patients. Current treatment options aim to prolong survival and improve quality of life. However, due to the heterogeneity of the disease, it isâ€¦

- **[DeepContrast: Deep Tissue Contrast Enhancement using Synthetic Data Degradations and OOD Model Predictions](https://arxiv.org/abs/2308.08365)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2308.08365v2 Announce Type: replace-cross 
Abstract: Microscopy images are crucial for life science research, allowing detailed inspection and characterization of cellular and tissue-level structures and functions. However, microscopy data are unavoidably affected by image degradations, such as noise, blur, or oâ€¦

- **[Guided rewiring of social networks reduces polarization and accelerates collective action](https://arxiv.org/abs/2309.12141)**  
  _Thu, 20 Nov 2025 00:00:00 -0500_  
  arXiv:2309.12141v2 Announce Type: replace-cross 
Abstract: Global social and ecological challenges represent collective action problems requiring rapid and sufficient cooperation with pro-mitigation norms. Sociopolitical polarization hinders such cooperation. Prior agent-based models showed polarization emerges naturaâ€¦
